// App-Quantinova.ai

8045 : Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).

Researchers

Presenter

  • Thomas G. Martin

Principal Investigators

  • Kwee Yong

  • Katja Weisel

  • Maneesha Mehra

  • Sandhya Nair

  • Keqin Qi

  • Anil Londhe

  • Joris Diels

  • Concetta Crivera

  • Carolyn Chang Jackson

  • Yunsi Olyslager

  • Martin Vogel

  • Jordan Mark Schecter

  • Arnob Banerjee

  • Satish Valluri

  • Saad Zafar Usmani

  • Jesus G. Berdeja

  • Sundar Jagannath

Medical Centers

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • City of Hope Comprehensive Cancer Center, Monrovia, CA

  • Kings College London, London, United Kingdom

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Janssen Global Services, Raritan, NJ

  • Janssen Pharmaceutica NV, Beerse, Belgium

  • Belgium

  • Janssen R&D, LLC, Titusville, NJ

  • Janssen R&D, LLC, Yardley, PA

  • Janssen R&D, Raritan, NJ

  • Janssen Pharmaceutica NV, Beerse, Belgium

  • Janssen, Spring House, PA

  • Levine Cancer Institute, Atrium Health, Charlotte, NC

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Mount Sinai Medical Center, New York, NY

Locations

  • United States

  • United Kingdom

  • Germany

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Pomalidomide

  • CC-4047

  • carfilzomib Intravenous

  • daratumumab Intravenous

  • Elotuzumab

  • Ixazomib

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • NCT03548207

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved